Flagship Pioneering Inc. - Q2 2018 holdings

$522 Million is the total value of Flagship Pioneering Inc.'s 7 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 25.0% .

 Value Shares↓ Weighting
EVLO NewEVELO BIOSCIENCES INC$215,154,00018,233,403
+100.0%
41.21%
DNLI  DENALI THERAPEUTICS INC$136,011,000
-22.5%
8,918,7490.0%26.05%
-48.8%
MCRB  SERES THERAPEUTICS INC$109,073,000
+17.2%
12,682,8760.0%20.89%
-22.6%
SYRS  SYROS PHARMACEUTICALS INC$32,717,000
-21.3%
3,204,4370.0%6.27%
-48.0%
QTRX  QUANTERIX CORP$29,158,000
-15.7%
2,030,4950.0%5.58%
-44.3%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-08-07
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SERES THERAPEUTICS INC29Q3 202368.0%
DENALI THERAPEUTICS INC24Q3 202350.9%
SYROS PHARMACEUTICALS INC24Q2 202227.3%
MODERNA INC20Q3 202376.9%
EVELO BIOSCIENCES INC20Q1 202341.2%
RUBIUS THERAPEUTICS INC18Q4 202260.7%
Axcella Health Inc17Q2 20233.5%
KALEIDO BIOSCIENCES INC13Q1 20229.5%
Foghorn Therapeutics Inc12Q3 20236.5%
Sana Biotechnology Inc11Q3 202318.4%

View Flagship Pioneering Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
42024-02-14
13F-HR2023-11-14
42023-09-15
42023-08-15
13F-HR2023-08-14
42023-07-13
13F-HR2023-05-15
42023-02-27
13F-HR2023-02-14

View Flagship Pioneering Inc.'s complete filings history.

Compare quarters

Export Flagship Pioneering Inc.'s holdings